文献速递糖尿病

CGM指标可预测1型糖尿病的临近进展:儿童自身免疫筛查(ASK)研究

CGM Metrics Predict Imminent Progression to Type 1 Diabetes: Autoimmunity Screening for Kids (ASK) Study.
PubMed 文献 · Diabetes Care · 2022-01-01

在儿童自身免疫筛查(ASK)研究中,91名持续胰岛自身抗体阳性且基线接受CGM的儿童随访中位6个月,16名(18%)进展为临床糖尿病。进展者平均传感器血糖119 vs 105 mg/dL(P<0.001),血糖变异指标均升高(均P<0.001);TA140>10%者1年进展风险80%,其余仅5%。作者认为CGM应纳入高危儿童随访,并可作为预防试验的潜在入组标准。

要点

  • 进展者平均传感器血糖119 vs 非进展者105 mg/dL(P<0.001),血糖变异性各指标均升高(均P<0.001)。
  • 进展者21%时间血糖>140 mg/dL、8%时间>160 mg/dL,非进展者分别为3%和1%。
  • TA140>10%者1年进展风险80%,其余参与者仅5%;单项与联合CGM指标模型AUC均≥0.89。

核心结论

  • 在自身抗体阳性儿童中,TA140>10%与未来1年内进展为临床糖尿病的高风险相关。
  • CGM应纳入高危儿童的持续监测,并可作为预防试验的潜在入组标准。

研究设计与样本

  • 儿童自身免疫筛查(ASK)研究纳入91名持续胰岛自身抗体阳性儿童,中位年龄11.5岁,48%为非西班牙裔白人,57%为女性,均有基线CGM。
  • 随访至发生糖尿病,中位随访6个月(范围0.2-34个月)。

主要发现

  • 16名(18%)进展为临床糖尿病,中位4.5个月(范围0.4-29个月)。
  • 进展者平均传感器血糖119 vs 非进展者105 mg/dL(P<0.001)。
  • 进展者血糖变异指标:SD 27 vs 16,变异系数21 vs 15,日间平均差值24 vs 16,血糖波动平均幅度43 vs 26(均P<0.001)。
  • 进展者21%时间血糖>140 mg/dL、8%时间>160 mg/dL,非进展者分别为3%和1%。
  • 生存分析:TA140>10%者1年进展风险80%,其余参与者5%;单项与联合CGM指标模型AUC均≥0.89。

关键数值与推荐

  • TA140>10%:1年进展为糖尿病风险80%;其余参与者1年风险5%。
  • 平均传感器血糖:进展者119 vs 非进展者105 mg/dL(P<0.001)。
  • 血糖变异SD:进展者27 vs 非进展者16;变异系数21 vs 15;日间平均差值24 vs 16;血糖波动平均幅度43 vs 26(均P<0.001)。
  • 血糖>140 mg/dL时间比例:进展者21% vs 非进展者3%;>160 mg/dL时间比例:进展者8% vs 非进展者1%。
  • 预测模型AUC:单项与联合CGM指标模型均≥0.89。

临床怎么用

  • 作者认为CGM应纳入高危儿童的持续监测,并可作为预防试验的潜在入组标准。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Children identified with stage 1 type 1 diabetes are at high risk for progressing to stage 3 (clinical) diabetes and require accurate monitoring. Our aim was to establish continuous glucose monitoring (CGM) metrics that could predict imminent progression to diabetes. RESEARCH DESIGN AND METHODS: In the Autoimmunity Screening for Kids study, 91 children who were persistently islet autoantibody positive (median age 11.5 years; 48% non-Hispanic White; 57% female) with a baseline CGM were followed for development of diabetes for a median of 6 (range 0.2-34) months. Of these, 16 (18%) progressed to clinical diabetes in a median of 4.5 (range 0.4-29) months. RESULTS: Compared with children who did not progress to clinical diabetes (nonprogressors), those who did (progressors) had significantly higher average sensor glucose levels (119 vs. 105 mg/dL, P < 0.001) and increased glycemic variability (SD 27 vs. 16, coefficient of variation, 21 vs. 15, mean of daily differences 24 vs. 16, and mean amplitude of glycemic excursions 43 vs. 26, all P < 0.001). For progressors, 21% of the time was spent with glucose levels >140 mg/dL (TA140) and 8% of time >160 mg/dL, compared with 3% and 1%, respectively, for nonprogressors. In survival analyses, the risk of progression to diabetes in 1 year was 80% in those with TA140 >10%; in contrast, it was only 5% in the other participants. Performance of prediction by receiver operating curve analyses showed area under the curve of ≥0.89 for both individual and combined CGM metric models. CONCLUSIONS: TA140 >10% is associated with a high risk of progression to clinical diabetes within the next year in autoantibody-positive children. CGM should be included in the ongoing monitoring of high-risk children and could be used as potential entry criterion for prevention trials.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Steck AK, Dong F, Geno Rasmussen C, et al. CGM Metrics Predict Imminent Progression to Type 1 Diabetes: Autoimmunity Screening for Kids (ASK) Study. Diabetes Care. 2022. PMID: 34880069. doi:10.2337/dc21-0602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。